Drug intelligence / Profile preview

POSIFORLID

Development stage
Unknown
Lead developer
URSAPHARM Arzneimittel
Modality
Small Molecules, Device-based Delivery → Drug Delivery Systems
01

Overview

POSIFORLID is a comprehensive product portfolio developed by Ursapharm for the treatment and management of eyelid inflammation (blepharitis) and meibomian gland dysfunction (MGD). The line includes POSIFORLID COMOD eye drops, which contain salicylic acid as an anti-inflammatory active ingredient for the treatment of blepharitis and conjunctivitis. Other components of the system include a self-heating eye mask (a medical device) designed to soften crusts and improve the flow of meibum at a constant temperature of approximately 45°C, an eye spray containing euphrasia and hyaluronic acid for supportive care, and eyelid hygiene wipes for gentle cleansing. The products are designed to work together as a coordinated 'concept for healthy eyelids' and are administered topically to the ocular area.

Brand names
POSIFORLIDPOSIFORLID COMOD
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on POSIFORLID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on POSIFORLID.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call